Contact
searchSearch
HMP Global

Prostate Cancer

News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
Bertrand Tombal, MD, PhD
Videos
Radium-223 Plus Enzalutamide Improves Survival in Bone-Predominant Metastatic Castration-Resistant Prostate Cancer
03/05/2026
Bertrand Tombal, MD, PhD
Bertrand Tombal, MD, PhD, discusses final overall survival results from the EORTC 1333/PEACE-3 trial evaluating enzalutamide with or without radium-223 in patients with metastatic castration-resistant prostate cancer and bone metastases.
Bertrand Tombal, MD, PhD, discusses final overall survival results from the EORTC 1333/PEACE-3 trial evaluating enzalutamide with or without radium-223 in patients with metastatic castration-resistant prostate cancer and bone metastases.
Bertrand Tombal, MD, PhD,...
03/05/2026
Radiopharmaceutical Education Institute
Alexander Wyatt, PhD
Videos
Clonal Hematopoiesis Expansion Following 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer
02/26/2026
Alexander Wyatt, PhD
Alexander Wyatt, PhD, discusses results from a post hoc correlative analysis of the phase 2 TheraP trial comparing 177Lu-PSMA-617 with standard cabazitaxel chemotherapy in patients with metastatic castration-resistant prostate cancer.
Alexander Wyatt, PhD, discusses results from a post hoc correlative analysis of the phase 2 TheraP trial comparing 177Lu-PSMA-617 with standard cabazitaxel chemotherapy in patients with metastatic castration-resistant prostate cancer.
Alexander Wyatt, PhD, discusses...
02/26/2026
Radiopharmaceutical Education Institute
Praful Ravi, MB, BChir, MRCP, Dana-Farber Cancer Institute
Videos
PSMA Radioligand Therapy in Hormone-Sensitive Prostate Cancer: Lessons from the PSMAddition Trial
02/12/2026
Praful Ravi, MB, BChir, MRCP
Praful Ravi, MB, BChir, MRCP, discusses the potential role of PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer, highlighting radiographic PFS benefits from the PSMAddition trial while emphasizing the need to balance...
Praful Ravi, MB, BChir, MRCP, discusses the potential role of PSMA radioligand therapy in metastatic hormone-sensitive prostate cancer, highlighting radiographic PFS benefits from the PSMAddition trial while emphasizing the need to balance...
Praful Ravi, MB, BChir, MRCP,...
02/12/2026
Radiopharmaceutical Education Institute
Mustafa Basree, DO, University of Wisconsin
Videos
Personalized Dosimetry Guides 177Lu-PSMA-617 Therapy in Prostate Cancer
02/06/2026
Mustafa Basree, DO
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses...
02/06/2026
Radiopharmaceutical Education Institute
Scott Tagawa, MD
Videos
Addition of 177Lu-PSMA-617 for Patients With Metastatic Hormone-Sensitive Prostate Cancer
10/30/2025
Scott Tagawa, MD
Scott Tagawa, MD, Weill Cornell Medicine, discusses results from the phase 3 PSMAddition trial evaluating the addition of 177Lu-PSMA-617 to androgen deprivation therapy and androgen receptor pathway inhibitor therapy for patients with...
Scott Tagawa, MD, Weill Cornell Medicine, discusses results from the phase 3 PSMAddition trial evaluating the addition of 177Lu-PSMA-617 to androgen deprivation therapy and androgen receptor pathway inhibitor therapy for patients with...
Scott Tagawa, MD, Weill Cornell...
10/30/2025
Radiopharmaceutical Education Institute
News
177Lu-PSMA-617 Added to Standard of Care Improves Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer
10/19/2025
Stephanie Holland
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...
Adding 177Lu-PSMA-617 to...
10/19/2025
Radiopharmaceutical Education Institute
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Radiopharmaceutical Education Institute
Conference Coverage
[177Lu]Lu-PSMA-617 Plus Enzalutamide Boosts Survival, Quality of Life for Poor-Risk Metastatic Castration-Resistant Prostate Cancer
02/13/2025
Allison Casey
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.
The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.
The addition of...
02/13/2025
Oncology
News
Sequencing of 177Lu-PSMA-617 and Cabazitaxel Did Not Significantly Impact Survival for Patients With Metastatic Castration-Resistant Prostate Cancer
01/21/2025
Stephanie Holland
According to results from the LuCaS trial, the sequence in which 177Lu-PSMA-617 and cabazitaxel was administered did not significantly impact survival outcomes among patients with metastatic castration-resistant prostate cancer.
According to results from the LuCaS trial, the sequence in which 177Lu-PSMA-617 and cabazitaxel was administered did not significantly impact survival outcomes among patients with metastatic castration-resistant prostate cancer.
According to results from the...
01/21/2025
Oncology

Advancing Oncology Through Radiopharmaceutical Innovation

The Radiopharmaceutical Education Institute (RPEI) is dedicated to advancing the science and clinical integration of radiopharmaceutical therapies in oncology. Through accessible, expert-driven education and multidisciplinary dialogue, we aim to equip clinicians with the insight and evidence needed to inform treatment decisions and shape the future of radiopharmaceutical innovation in cancer care.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use